View in EDS PDF Full Text

Tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the Asian subgroup of the RATIONALE-305 study.

Saved in:
Bibliographic Details
Title: Tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the Asian subgroup of the RATIONALE-305 study.
Authors: Kato K; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Xu RH; Collaborative Innovation Center of Cancer Medicine, Department of Medical Oncology, University Cancer Center State Key Laboratory of Oncology in South China, Guangzhou, China., Oh DY; Department of Internal Medicine, Seoul National University Hospital Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea., Bai Y; Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China., Shi J; Department II of Medical Oncology, Linyi Cancer Hospital, Linyi, China., Lee KW; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea., Hirano H; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Xu H; Clinical Development, BeOne Medicines, Ltd, Beijing, China., Sheng T; Biostatistics/Clinical Development, BeOne Medicines, Ltd, Beijing, China., B Barnes F; Patient-Reported Outcomes Function, Global Medical Affairs, BeOne Medicines, Ltd, San Carlos, CA, USA., Barnes G; Patient-Reported Outcomes Function, Global Medical Affairs, BeOne Medicines, Ltd, San Carlos, CA, USA.
Source: Current medical research and opinion [Curr Med Res Opin] 2026 Jun 09, pp. 1-11. Date of Electronic Publication: 2026 Jun 09.
Publication Type: Journal Article
Journal Info: Publisher: Informa Healthcare Country of Publication: England NLM ID: 0351014 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-4877 (Electronic) Linking ISSN: 03007995 NLM ISO Abbreviation: Curr Med Res Opin Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42262249
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the Asian subgroup of the RATIONALE-305 study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kato+K%22">Kato K</searchLink>; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Xu+RH%22">Xu RH</searchLink>; Collaborative Innovation Center of Cancer Medicine, Department of Medical Oncology, University Cancer Center State Key Laboratory of Oncology in South China, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Oh+DY%22">Oh DY</searchLink>; Department of Internal Medicine, Seoul National University Hospital Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Bai+Y%22">Bai Y</searchLink>; Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China.<br /><searchLink fieldCode="AU" term="%22Shi+J%22">Shi J</searchLink>; Department II of Medical Oncology, Linyi Cancer Hospital, Linyi, China.<br /><searchLink fieldCode="AU" term="%22Lee+KW%22">Lee KW</searchLink>; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Hirano+H%22">Hirano H</searchLink>; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Xu+H%22">Xu H</searchLink>; Clinical Development, BeOne Medicines, Ltd, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Sheng+T%22">Sheng T</searchLink>; Biostatistics/Clinical Development, BeOne Medicines, Ltd, Beijing, China.<br /><searchLink fieldCode="AU" term="%22B+Barnes+F%22">B Barnes F</searchLink>; Patient-Reported Outcomes Function, Global Medical Affairs, BeOne Medicines, Ltd, San Carlos, CA, USA.<br /><searchLink fieldCode="AU" term="%22Barnes+G%22">Barnes G</searchLink>; Patient-Reported Outcomes Function, Global Medical Affairs, BeOne Medicines, Ltd, San Carlos, CA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220351014%22">Current medical research and opinion</searchLink> [Curr Med Res Opin] 2026 Jun 09, pp. 1-11. <i>Date of Electronic Publication: </i>2026 Jun 09.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Informa+Healthcare%22">Informa Healthcare </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>0351014 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1473-4877 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203007995%22">03007995 </searchLink><i>NLM ISO Abbreviation: </i>Curr Med Res Opin <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42262249
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/03007995.2026.2682010
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1
    Titles:
      – TitleFull: Tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the Asian subgroup of the RATIONALE-305 study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kato K
      – PersonEntity:
          Name:
            NameFull: Xu RH
      – PersonEntity:
          Name:
            NameFull: Oh DY
      – PersonEntity:
          Name:
            NameFull: Bai Y
      – PersonEntity:
          Name:
            NameFull: Shi J
      – PersonEntity:
          Name:
            NameFull: Lee KW
      – PersonEntity:
          Name:
            NameFull: Hirano H
      – PersonEntity:
          Name:
            NameFull: Xu H
      – PersonEntity:
          Name:
            NameFull: Sheng T
      – PersonEntity:
          Name:
            NameFull: B Barnes F
      – PersonEntity:
          Name:
            NameFull: Barnes G
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 09
              M: 06
              Text: 2026 Jun 09
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1473-4877
          Titles:
            – TitleFull: Current medical research and opinion
              Type: main
ResultId 1